Treatment of resistance to Ruxolitinib cream

In clinical studies of ruxolitinib cream, patients reported rapid improvement in quality of life and pruritus symptoms following treatment with ruxolitinib cream. By week 2, mean Skindex-16 and pruritus NRS scores both dropped by more than half and continued to decline gradually throughout treatment in most patients. However, based on previous research on Th2-driven itch mediated by JAK1, as well as clinical findings, JAK1 and/or 2 may play a key role.

However, some patients may develop resistance to ruxolitinib cream due to long-term use or other reasons. Patients should inform their doctors in time, and the doctors will comprehensively consider the patient's condition and drug resistance to re-evaluate the treatment plan. Further examination and testing may be needed to determine if the dosage of medication needs to be adjusted or another treatment may need to be changed. In some cases, your doctor may recommend combining ruxolitinib cream with other medications to enhance the effectiveness of treatment. Combination therapy can act on skin lesions through different mechanisms, thereby reducing dependence on a single drug.

The original drug of ruxolitinib cream has not yet been marketed in China, so it cannot be included in medical insurance. The price of ruxolitinib cream Original drug, specificationsinn 1.5%*60g, which is marketed overseas, is around RMB 20,000 per tube (the price may fluctuate due to the exchange rate), which is relatively expensive. The price of generic ruxolitinib cream marketed overseas is relatively cheap, and its pharmaceutical ingredients are basically the same as those of the original drug. The price of the specificationinn 1.5%*30g produced by a Bangladesh pharmaceutical factory is around 600 yuan per tube (the price may fluctuate due to exchange rate effects).